cs.AIOct 30, 2026

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

Authors: Russell Ro, Reza Abbasi-Asl

Organizations: University of California, San Francisco · University of California, Berkeley

Abstract

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's κqw=0.694±0.096κ_{qw} = 0.694 \pm 0.096). The best open-weight model, Gemma 2 9B, achieves κqwκ_{qw}-aligned ordinal score 3.0±0.93.0 \pm 0.9 on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches 3.0±0.83.0 \pm 0.8 (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

Figures & tables

Appendix figures & tables1 asset

Supplementary material from the paper’s appendix.

Appendix

Explore similar work

Apr 3, 2026

Eligibility-Aware Evidence Synthesis: An Agentic Framework for Clinical Trial Meta-Analysis

Clinical evidence synthesis requires identifying relevant trials from large registries and aggregating results that account for population differences. While recent LLM-based approaches have automated components of systematic review, they do not support end-to-end evidence synthesis. Moreover, conventional meta-analysis weights studies by statistical precision without considering clinical compatibility reflected in eligibility criteria. We propose EligMeta, an agentic framework that integrates automated trial discovery with eligibility-aware meta-analysis, translating natural-language queries into reproducible trial selection and incorporating eligibility alignment into study weighting to produce cohort-specific pooled estimates. EligMeta employs a hybrid architecture separating LLM-based reasoning from deterministic execution: LLMs generate interpretable rules from natural-language queries and perform schema-constrained parsing of trial metadata, while all logical operations, weight computations, and statistical pooling are executed deterministically to ensure reproducibility. The framework structures eligibility criteria and computes similarity-based study weights reflecting population alignment between target and comparator trials. In a gastric cancer landscape analysis, EligMeta reduced 4,044 candidate trials to 39 clinically relevant studies through rule-based filtering, recovering all 13 guideline-cited trials. In an olaparib adverse events meta-analysis across four trials, eligibility-aware weighting shifted the pooled risk ratio from 2.18 (95% CI: 1.71-2.79) under conventional Mantel-Haenszel estimation to 1.97 (95% CI: 1.76-2.20), demonstrating quantifiable impact of incorporating eligibility alignment. EligMeta bridges automated trial discovery with eligibility-aware meta-analysis, providing a scalable and reproducible framework for evidence synthesis in precision medicine.
Nov 6, 2026

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.
Apr 6, 2026

Retrieval-Augmented LLMs for Evidence Localization in Clinical Trial Recruitment from Longitudinal EHR Narratives

Screening patients for enrollment is a well-known, labor-intensive bottleneck that leads to under-enrollment and, ultimately, trial failures. Recent breakthroughs in large language models (LLMs) offer a promising opportunity to use artificial intelligence to improve screening. This study systematically explored both encoder- and decoder-based generative LLMs for screening clinical narratives to facilitate clinical trial recruitment. We examined both general-purpose LLMs and medical-adapted LLMs and explored three strategies to alleviate the "Lost in the Middle" issue when handling long documents, including 1) Original long-context: using the default context windows of LLMs, 2) NER-based extractive summarization: converting the long document into summarizations using named entity recognition, 3) RAG: dynamic evidence retrieval based on eligibility criteria. The 2018 N2C2 Track 1 benchmark dataset is used for evaluation. Our experimental results show that the MedGemma model with the RAG strategy achieved the best micro-F1 score of 89.05%, outperforming other models. Generative LLMs have remarkably improved trial criteria that require long-term reasoning across long documents, whereas trial criteria that span a short piece of context (e.g., lab tests) show incremental improvements. The real-world adoption of LLMs for trial recruitment must consider specific criteria for selecting among rule-based queries, encoder-based LLMs, and generative LLMs to maximize efficiency within reasonable computing costs.